Mirum Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MIRM and other ETFs, options, and stocks.

About MIRM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. 

CEO
Christopher Peetz
CEOChristopher Peetz
Employees
372
Employees372
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
2018
Founded2018
Employees
372
Employees372

MIRM Key Statistics

Market cap
5.51B
Market cap5.51B
Price-Earnings ratio
-201.95
Price-Earnings ratio-201.95
Dividend yield
Dividend yield
Average volume
868.86K
Average volume868.86K
High today
$96.58
High today$96.58
Low today
$90.91
Low today$90.91
Open price
$95.15
Open price$95.15
Volume
237.54K
Volume237.54K
52 Week high
$109.28
52 Week high$109.28
52 Week low
$36.88
52 Week low$36.88

Stock Snapshot

The current Mirum Pharmaceuticals(MIRM) stock price is $91.39, with a market capitalization of 5.51B. The stock trades at a price-to-earnings (P/E) ratio of -201.95.

On 2026-03-18, Mirum Pharmaceuticals(MIRM) stock traded between a low of $90.91 and a high of $96.58. Shares are currently priced at $91.39, which is +0.5% above the low and -5.4% below the high.

The Mirum Pharmaceuticals(MIRM)'s current trading volume is 237.54K, compared to an average daily volume of 868.86K.

During the past year, Mirum Pharmaceuticals(MIRM) stock moved between $36.88 at its lowest and $109.28 at its peak.

During the past year, Mirum Pharmaceuticals(MIRM) stock moved between $36.88 at its lowest and $109.28 at its peak.

MIRM News

TipRanks 2d
Mirum Pharmaceuticals completes enrollment in EXPAND study

Mirum Pharmaceuticals (MIRM) announced completion of enrollment in EXPAND, a Phase 3 randomized, double-blind, placebo-controlled study evaluating Livmarli for...

Simply Wall St 6d
Does Advancing Brelovitug Into Late-Stage HDV Trials Change The Bull Case For Mirum Pharmaceuticals?

In early March 2026, Mirum Pharmaceuticals reported that it had completed enrollment in its Phase 3 AZURE-1 trial and completed screening in its Phase 3 AZURE-4...

Does Advancing Brelovitug Into Late-Stage HDV Trials Change The Bull Case For Mirum Pharmaceuticals?

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own MIRM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.